LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Account Payables

Last Annual Value

2.13M

3-Year CAGR

139%

5-Year CAGR

69%

10-Year CAGR

30%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Account Payables

LBRX · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.13M
15.3%N/AN/A 
1.55M
-4.7%-8.4%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
14.93M
39.6%6.0%N/A
2.60M
-32.0%-12.4%-5.6%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
5.40M
-5.9%20.9%N/A
5.31M
6.8%47.0%N/A
2.89M
-15.6%-2.0%N/A
12.46M
32.4%39.5%N/A
3.58M
-14.0%-19.7%N/A
0.00
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
1.65M
-39.0%-9.7%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95